AMENDMENTS TO THE CLAIMS

1-2. **(Cancelled)**

3. **(Currently amended)** An oral sustained-release tablet comprising a pharmaceutical composition containing:

_____4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as an active ingredient in an amount of 0.2 to 0.7 mg, and ~~wherein the pharmaceutical composition contains~~

_____18 to 73wt% of hydroxypropylmethylcellulose as a gel-forming material,

_____wherein the hydroxypropylmethylcellulose has an average viscosity of 4000 cps.

4. **(Currently amended)** The oral sustained-release tablet according to claim 3, obtained by mixing a granular composition, in which 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide is uniformly dispersed by means of fluidized bed granulation method, with a composition containing ~~a~~ the gel-forming material which is hydroxypropylmethylcellulose~~ to manufacture a granular formulation for making tablets~~.

5. **(Previously presented)** The oral sustained-release tablet according to claim 4, wherein the granular composition is manufactured by using a solution of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide and by spraying the solution on partly pregelatinized starch.